Literature DB >> 11562193

Prolonged in vivo residence times of antibody fragments associated with albumin.

B J Smith1, A Popplewell, D Athwal, A P Chapman, S Heywood, S M West, B Carrington, A Nesbitt, A D Lawson, P Antoniw, A Eddelston, A Suitters.   

Abstract

Antibody fragments can be expressed at a high level in microbial systems, but they may have limited therapeutic value because they are rapidly eliminated from the body. We demonstrate here that site-specific conjugation or binding of bacterially derived Fab' to the long-lived protein serum albumin allows full retention of the antibody's binding characteristics while imparting the albumin's longevity in vivo. In rats the area under the curve for Fab' conjugated to rat serum albumin was 17-fold greater than for the control of Fab' conjugated to cysteine. Again, a bispecific F(ab')(2) with specificity for rat serum albumin showed an area under the curve about 8-fold greater than did a F(ab')(2) without specificity to albumin. Genetic fusions of scFv to albumin were similarly long-lived and could be expressed in yeast to provide the basis of a cost-effective production system.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11562193     DOI: 10.1021/bc010003g

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  18 in total

1.  Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein.

Authors:  Paul J Yazaki; Thewodros Kassa; Chia-wei Cheung; Desiree M Crow; Mark A Sherman; James R Bading; Anne-Line J Anderson; David Colcher; Andrew Raubitschek
Journal:  Nucl Med Biol       Date:  2008-02       Impact factor: 2.408

2.  5th Annual Monoclonal Antibodies Conference: March 24-25, 2009, London, UK.

Authors:  Mari Herigstad; Lisa Urquhart
Journal:  MAbs       Date:  2009 Jul-Aug       Impact factor: 5.857

3.  Antagonist properties of monoclonal antibodies targeting human CD28: role of valency and the heavy-chain constant domain.

Authors:  Caroline Mary; Flora Coulon; Nicolas Poirier; Nahzli Dilek; Bernard Martinet; Gilles Blancho; Bernard Vanhove
Journal:  MAbs       Date:  2012-12-05       Impact factor: 5.857

4.  Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain.

Authors:  Mischa R Müller; Kenneth Saunders; Christopher Grace; Macy Jin; Nicole Piche-Nicholas; John Steven; Ronan O'Dwyer; Leeying Wu; Lam Khetemenee; Yulia Vugmeyster; Timothy P Hickling; Lioudmila Tchistiakova; Stephane Olland; Davinder Gill; Allan Jensen; Caroline J Barelle
Journal:  MAbs       Date:  2012 Nov-Dec       Impact factor: 5.857

5.  Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain.

Authors:  Jan Terje Andersen; Rikard Pehrson; Vladimir Tolmachev; Muluneh Bekele Daba; Lars Abrahmsén; Caroline Ekblad
Journal:  J Biol Chem       Date:  2010-12-07       Impact factor: 5.157

6.  Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding.

Authors:  Jan Terje Andersen; Muluneh Bekele Daba; Gøril Berntzen; Terje E Michaelsen; Inger Sandlie
Journal:  J Biol Chem       Date:  2009-12-14       Impact factor: 5.157

Review 7.  Neonatal Fc receptor: from immunity to therapeutics.

Authors:  Timothy T Kuo; Kristi Baker; Masaru Yoshida; Shuo-Wang Qiao; Victoria G Aveson; Wayne I Lencer; Richard S Blumberg
Journal:  J Clin Immunol       Date:  2010-10-01       Impact factor: 8.317

Review 8.  Development of genetically engineered human sperm immunocontraceptives.

Authors:  Rajesh K Naz
Journal:  J Reprod Immunol       Date:  2009-10-23       Impact factor: 4.054

9.  Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics.

Authors:  Jan Terje Andersen; Jason Cameron; Andrew Plumridge; Leslie Evans; Darrell Sleep; Inger Sandlie
Journal:  J Biol Chem       Date:  2013-07-01       Impact factor: 5.157

10.  Isolation of human single chain variable fragment antibodies against specific sperm antigens for immunocontraceptive development.

Authors:  A S Samuel; R K Naz
Journal:  Hum Reprod       Date:  2008-03-26       Impact factor: 6.918

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.